Vernalis Stock

Equities

VER

Biotechnology & Medical Research

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		+0.65%	-29.32%

2017

Vernalis : hit by fresh U.S. setback for cough and cold drug

RE

on all our subscriptions*

Take advantage of the offer

* See conditions on site

Chart Vernalis

Duration

Period

Style

Latest news about Vernalis

Vernalis : hit by fresh U.S. setback for cough and cold drug

17-08-07

RE

Press releases Vernalis

Vernalis : AGM Statement	17-12-14	PU
Vernalis PLC: AGM Statement	17-12-14	MW
Vernalis : enters into research collaboration with Daiichi Sankyo	17-12-13	PU
Vernalis : + Daiichi Sankyo Enter Collaboration	17-12-13	MW
Vernalis : and Servier Achieve Research Milestone in Third Oncology Collaboration	17-12-06	PU

More press releases

Managers and Directors - Vernalis

Managers	Title	Age	Since
Timothy Cowper DFI	Director of Finance/CFO	-	-
Sandford Sommer PSD	President	-	16-04-30
Mike Wood CTO	Chief Tech/Sci/R&D Officer	-	04-01-31

Members of the board	Title	Age	Since
Matthew Foehr BRD	Director/Board Member	51	18-10-11
Charles Berkman BRD	Director/Board Member	55	18-10-11
Matthew Korenberg BRD	Director/Board Member	49	18-10-11

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+21.74%	46.4B
IQVIA HOLDINGS INC.	-0.97%	41.75B
LONZA GROUP AG	+48.77%	41.37B
CELLTRION, INC.	-3.52%	29.71B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.52B
MEDPACE HOLDINGS, INC.	+31.18%	12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.13B
BIO-TECHNE CORPORATION	+0.39%	12.18B

Other Biotechnology & Medical Research

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW